Thread by @mukesh_rai

@LaurusLabs
#lauruslabs
#Laurus

Laurus Q4 concall (first hand notes)

CDMO / synthesis is crying but management says that they have delivered all what they had in hand and going forward also..
CDMO revenue can't be in linear growth scale & will be lumpy

CDMO : active projects are ~60

CDMO / BIO revenue contribution was ~20% in last FY & it can scale upto ~50% in 5 years

Margins will improve from current levels

no guidance on quarterly basis & we need to consider annual guidance only

Global fund ARV tender's shipment already started

Confidence is missing in body language as well

Tax rate will revert to normal levels of 25% from 29%

Earlier said that fy24 is consolidation but now for consolation ..says in concall that capex will help in second half

An investor directly & rightly tells upfront that have some cognizance while speaking about future guidance (in plain words... speak less & perform more)

first ARV & now CDMO... they have one or other excuse to show dismal performance

when people are asking about last quarter or FY... they are providing comparison of 5 years FY18 vs FY23

Note : I may be biased or have heard or understood incorrectly, please do due diligence before consuming it & taking any investment decision